Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib

R. A. Abdelrahman, K. H. Begna, A. Al-Kali, W. J. Hogan, M. R. Litzow, A. Tefferi

Research output: Contribution to journalLetterpeer-review

10 Scopus citations
Original languageEnglish (US)
Pages (from-to)498-500
Number of pages3
Issue number2
StatePublished - Feb 7 2015

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this